基本信息
浏览量:77
职业迁徙
个人简介
NeuroEM Therapeutics, Inc is a clinical-stage medical device company committed to developing, clinically testing, and marketing Transcranial ElectroMagnetic Treatment (TEMT) as an effective prevention and treatment for Alzheimer’s Disease & other neurodegenerative diseases. The pioneering TEMT technology developed by Dr. Arendash and NeuroEM Therapeutics has shown extraordinary promise in 6 published pre-clinical studies, a completed and published clinical trial, and two extension clinical trials. NeuroEM Therapeutics has found that their patent-protected device [MemorEM] can reverse cognitive impairment and stabilize cognitive performance, and activities of daily living for well over 2 years. This unique neuromodulatory approach against AD was given the FDA's "breakthrough" designation in 2020 -- the first device or drug to be so designated against AD. NeuroEM has identified multiple disease-modifying mechanisms of action for TEMT against AD, including the unique ability to disaggregate oligomers of both toxins now thought to be root causes of AD and the ability to greatly enhance mitochondrial function in neurons. The company is presently embarking on a Phase 2 clinical before an anticipated pivotal trial in AD subjects. Dr Arendash believes TEMT technology is the future for treatment of many diseases of aging, so that health span can be substantially extended.
研究兴趣
论文共 143 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
International journal of molecular sciencesno. 11 (2023): 9652-9652
Gary Arendash,Haitham Abulaban,Susan Steen,Ross Andel,Yanhong Wang,Yun Bai,Rob Baranowski, Jon McGarity, Lyle Scritsmier,Xiaoyang Lin,Ning Shen, Ali Aljassabi,Yitong Li,Chuanhai Cao
mag(2014)
引用23浏览0引用
23
0
加载更多
作者统计
#Papers: 149
#Citation: 13938
H-Index: 58
G-Index: 117
Sociability: 7
Diversity: 3
Activity: 2
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn